Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patient start forms received, including 207 in the fourth quarter630 unique prescribers, including 136 new prescribers in the fourth quarter859 active patients on drug as of December 31, 2025Over 185 million lives covered Achieved profitability with positive net income of $20.9 million for the year.Gene
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics (SLNO) had its price target lowered by HC Wainwright from $120.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy [Yahoo! Finance]Yahoo! Finance
- Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Soleno Profitability Milestone And CFO Shift Raise Valuation Questions [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
SLNO
Earnings
- 2/25/26 - Beat
SLNO
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 3
- 2/26/26 - Form 8-K
- SLNO's page on the SEC website